Skip to main content
RPRXRoyalty Pharma plcHold5.2·$63.78-0.15%

Royalty Pharma (RPRX) Q2 2026 earnings — TrendMatrix coverage

BEAT+3.9% vs estimateEPS $1.32 vs $1.27 estVerdict Buy (Wait)Sell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.32
Estimate
$1.27
Surprise
+3.9%
Revenue (period 2026-06-30)
$674.1M
Score at report (before → after)
5.25.4/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Royalty Pharma (RPRX) beat the $1.27 estimate with diluted EPS of $1.32 — a clear 3.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.2/10) to Sell at 5.4/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates RPRX Hold at 5.2/10.

4 of the last 4 quarters beat the estimate; this quarter's +3.9% surprise compares with a +8.9% four-quarter average. Next scheduled report: 2026-11-04.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Analyst target reached - limited upside remaining
  • Near 52-week high (0.3% away)
  • Weak growth

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$63.78
Price target
$73.30
Stop
$61.18
Upside to target
+14.9%

The stock trades at 33.8× trailing but 11.1× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

RPRX at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$36.91B
P/E (fwd)
11.1
P/E (ttm)
33.8
52-week range
$34.08$63.94
Off 52-week high
0.3%
RSI (14)
72
Volume vs avg
0.74×
Score today
5.2/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks RPRX Earnings Q2 2026 earnings